Zhuhai Trinomab Pharmaceutical Co., Ltd. Class A

As of June 30, 2026, Zhuhai Trinomab Pharmaceutical Co., Ltd. Class A has 391.46M shares outstanding.

As of June 30, 2026, Zhuhai Trinomab Pharmaceutical Co., Ltd. Class A maintains a current ratio of 1.83, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1,087.54, indicating moderate leverage, while an interest coverage ratio of -17.93 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 60,868.37 in revenue per employee across its workforce of 843.00, a quick read on workforce productivity versus industry peers.

These figures are as of the close on October 22, 2026.

These figures cover the twelve months ended June 30, 2026.

As of June 30, 2026, Zhuhai Trinomab Pharmaceutical Co., Ltd. Class A holds 553.93M in cash and equivalents against 843.99M in total debt, resulting in a net debt position of -14.07M. Total book value stands at 51.36M, with working capital of 354.72M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Zhuhai Trinomab Pharmaceutical Co., Ltd. Class A posted a gross margin of 74.27, reflecting its pricing power and cost economics. The operating margin of -184.25 and net profit margin of -200.67 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Zhuhai Trinomab Pharmaceutical Co., Ltd. Class A paid dividends of 0.01 per share. The dividend payout ratio of -4.91 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.